Tomlins SA / Bernstein / Future Medicine Ltd / Li LC / Nucleosomes / ADP / PET / Histone / /
Country
United States / China / / /
Event
Reorganization / /
Facility
National Cancer Institute / Baylor College of Medicine / The Ohio State University / / /
IndustryTerm
start site / treatment of this disease / treatment of prostate cancer / particular binding site / science / treatment for advanced androgen-dependent prostate cancer / genetic and epigenetic regulatory networks / /
MedicalCondition
androgen-independent prostate cancer / DF / rP ro prostate cancer / metastatic prostate cancer / prostate carcinogenesis / common noncutaneous cancer / castration-resistant prostate cancer / prostate cancer A / benign prostatic hyperplasia / prostate cancer / receptor-dependent prostate cancer / low-grade tumors / tumor / cancer / disease / different cancers / prostatic carcinogenesis / low-grade prostate tumors / prostate and other cancers / localized prostate cancer / fatal castration-resistant disease / advanced androgen-dependent prostate cancer / human prostate cancer / androgen-refractory prostate cancer / androgen-dependent prostate cancer / prostate carcinoma / /
MedicalTreatment
prostatectomy / AID / /
Organization
National Cancer Institute / The Ohio State University / Columbus / Zhong Chen1* / Liguo Wang2* / Qianben Wang†1 & Wei Li†2 Department of Molecular and Cellular Biochemistry / Baylor College of Medicine / Houston / Ohio State University Comprehensive Cancer Center / Department of Defense / Cellular Biochemistry & Comprehensive Cancer Center / /
Person
Wei Li / Gene Regul / Van Steensel / Nat / Van Deursen / Van Ree / Weigel Huang / Anna Rorick / Van Berkum / Tim Huang / / /
Position
mediator / Author / Cao / prostate cancer AR ARE Mediator / Nancy Executive / /